Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Subscribe To Our Newsletter & Stay Updated